Literature DB >> 14531938

Expression of core binding factor alpha1 up-regulated by IGF-I, GM-CSF, and EGF through MAPK pathway in MC3T3-E1 and C2C12 cells.

Yu Pei1, Xun-Wu Meng, Xue-Ying Zhou, Xiao-Ping Xing, Wei-Bo Xia.   

Abstract

AIM: To study the regulating function and mechanism of insulin-like growth factor-I (IGF-I), granulocyte-macrophage colony-stimulating factor (GM-CSF), and epidermal growth factor (EGF) on murine core binding factor alpha1 (Cbfalpha1) gene expression.
METHODS: Luciferase reporter gene method and RT-PCR technique were used to examine the effects of these growth factors on the promoter activity and mRNA expression of Cbfalpha1 gene in MC3T3-E1 and C2C12 cells.
RESULTS: IGF-I (from 1 nmol/L to 1 micromol/L), GM-CSF (100 nmol/L), and EGF (1 micromol/L) increased the luciferase expression in MC3T3-E1 cells (P<0.05). And mitogen-activated protein kinase (MAPK) inhibitor, PD 98059 (10 micromol/L), completely blocked IGF-1, GM-CSF, and EGF-induced expression of Cbfa1 promoter activity (P<0.01). In C2C12 cells, IGF-I (from 1 nmol/L to 10 micromol/L), GM-CSF (100 nmol/L and 1 micromol/L), and EGF (100 nmol/L) enhanced the expression of luciferase reporter plasmid driven by mCbfalpha1 promoter (P<0.05). Addition of PD 98059 also blocked the stimulatory effects of these growth factors on Cbfalpha1 promoter activity (P<0.01). Moreover, Cbfalpha1 mRNA expression was significantly increased after treatment with IGF-I (1 nmol/L, 100 nmol/L), GM-CSF (100 nmol/L, 1 micromol/L), and EGF (1 micromol/L, 100 nmol/L) in MC3T3-E1 and C2C12 cells, respectively (P<0.05). These stimulatory effects of IGF-I, GM-CSF, and EGF on Cbfalpha1 mRNA expression were abolished by PD 98059.
CONCLUSION: IGF-I, GM-CSF, and EGF could increase the promoter activity and the mRNA expression of murine Cbfalpha1 gene in MC3T3-E1 and C2C12 cells. These stimulatory effects might be mediated by activating the intracellular MAPK-dependent signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14531938

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  5 in total

1.  Calvarial cleidocraniodysplasia-like defects with ENU-induced Nell-1 deficiency.

Authors:  Xinli Zhang; Kang Ting; Dharmini Pathmanathan; Theodore Ko; Weiwei Chen; Feng Chen; Haofu Lee; Aaron W James; Ronald K Siu; Jia Shen; Cymbeline T Culiat; Chia Soo
Journal:  J Craniofac Surg       Date:  2012-01       Impact factor: 1.046

2.  IGF-I regulates tight-junction protein claudin-1 during differentiation of osteoblast-like MC3T3-E1 cells via a MAP-kinase pathway.

Authors:  Naoko Hatakeyama; Takashi Kojima; Kousuke Iba; Masaki Murata; Mia M Thi; David C Spray; Makoto Osanai; Hideki Chiba; Sumio Ishiai; Toshihiko Yamashita; Norimasa Sawada
Journal:  Cell Tissue Res       Date:  2008-10-15       Impact factor: 5.249

3.  Nell-1, a key functional mediator of Runx2, partially rescues calvarial defects in Runx2(+/-) mice.

Authors:  Xinli Zhang; Kang Ting; Catherine M Bessette; Cymbeline T Culiat; Sang Jin Sung; Haofu Lee; Feng Chen; Jia Shen; James J Wang; Shun'ichi Kuroda; Chia Soo
Journal:  J Bone Miner Res       Date:  2011-04       Impact factor: 6.741

4.  Thyroid-Stimulating Hormone Favors Runx2-Mediated Matrix Mineralization in HOS and SaOS2 Cells: An In Vitro and In Silico Approach.

Authors:  Ramajayam Govindan; Mohamed El-Sherbiny; Khalid Mohamed Morsy Ibraheem; Srinivasan Narasimhan; Mohamed El-Dosoky Mohamed Salama; Fazil Ahmad; Selvaraj Jayaraman; Vishnu Priya Veeraraghavan; Srinivasan Vengadassalapathy; Surapaneni Krishna Mohan; Vidhya Rekha Umapathy; Gayathri Rengasamy; Shazia Fathima Jaffer Hussain; Maheshkumar Poomarimuthu; Senthilkumar Kalimuthu
Journal:  Molecules       Date:  2022-01-18       Impact factor: 4.411

5.  Actin microfilament mediates osteoblast Cbfa1 responsiveness to BMP2 under simulated microgravity.

Authors:  Zhongquan Dai; Feng Wu; Jian Chen; Hongjie Xu; Honghui Wang; Feima Guo; Yingjun Tan; Bai Ding; Jinfu Wang; Yumin Wan; Yinghui Li
Journal:  PLoS One       Date:  2013-05-10       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.